CA2371900A1 - Cellules-2 pluripotentes - Google Patents

Cellules-2 pluripotentes Download PDF

Info

Publication number
CA2371900A1
CA2371900A1 CA002371900A CA2371900A CA2371900A1 CA 2371900 A1 CA2371900 A1 CA 2371900A1 CA 002371900 A CA002371900 A CA 002371900A CA 2371900 A CA2371900 A CA 2371900A CA 2371900 A1 CA2371900 A1 CA 2371900A1
Authority
CA
Canada
Prior art keywords
cell
cells
pluripotential
nucleus
somatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002371900A
Other languages
English (en)
Inventor
Peter Andrews
Paul Kemp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intercytex Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2371900A1 publication Critical patent/CA2371900A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0611—Primordial germ cells, e.g. embryonic germ cells [EG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/04—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from germ cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/04—Cells produced using nuclear transfer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)

Abstract

La présente invention concerne des cellules isolées pluripotentes comprenant au moins une partie du cytoplasme dérivé d'une cellule souche/germinale embryonnaire et un noyau d'une cellule somatique. L'invention se rapporte aussi à des procédés de préparation de telles cellules ainsi qu'à des compositions thérapeutiques contenant lesdites cellules.
CA002371900A 1999-02-20 2000-02-18 Cellules-2 pluripotentes Abandoned CA2371900A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9903804.4 1999-02-20
GBGB9903804.4A GB9903804D0 (en) 1999-02-20 1999-02-20 Pluripotential cells-2
PCT/GB2000/000576 WO2000049137A2 (fr) 1999-02-20 2000-02-18 Cellules-2 pluripotentes

Publications (1)

Publication Number Publication Date
CA2371900A1 true CA2371900A1 (fr) 2000-08-24

Family

ID=10848084

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002371900A Abandoned CA2371900A1 (fr) 1999-02-20 2000-02-18 Cellules-2 pluripotentes

Country Status (7)

Country Link
EP (1) EP1153123A2 (fr)
JP (1) JP2003514509A (fr)
AU (1) AU2563600A (fr)
CA (1) CA2371900A1 (fr)
GB (1) GB9903804D0 (fr)
HK (2) HK1040741A1 (fr)
WO (1) WO2000049137A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1368402A (en) * 2000-11-09 2002-05-21 Bresagen Ltd Cell reprogramming
CA2461185A1 (fr) * 2001-09-21 2003-04-03 Japan Science And Technology Corporation Procede de criblage de facteur de reprogrammation, facteur de reprogrammation crible au moyen de ce procede, procede d'utilisation du facteur de reprogrammation, procede de differenciation de cellules fusionnees non differenciees et procede de construction de cellules, de tissus et d'organes
JP2004248505A (ja) * 2001-09-21 2004-09-09 Norio Nakatsuji 移植抗原の一部または全てを欠除したｅｓ細胞由来の未分化な体細胞融合細胞およびその製造
US7704738B2 (en) 2003-12-23 2010-04-27 Cythera, Inc. Definitive endoderm
US8647873B2 (en) 2004-04-27 2014-02-11 Viacyte, Inc. PDX1 expressing endoderm
CA2640644C (fr) 2006-01-31 2013-11-26 Asubio Pharma Co., Ltd. Procede de purification des cardiomyocytes ou des cardiomyocytes programmes et derives de cellules souches ou de fetus
EP2014766A4 (fr) 2006-04-28 2009-12-02 Asubio Pharma Co Ltd Procédé pour induction de la différenciation de cellules du myocarde à partir de cellules souches pluripotentes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9517780D0 (en) * 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation

Also Published As

Publication number Publication date
WO2000049137B1 (fr) 2001-05-17
EP1153123A2 (fr) 2001-11-14
WO2000049137A2 (fr) 2000-08-24
AU2563600A (en) 2000-09-04
HK1042112A1 (zh) 2002-08-02
WO2000049137A3 (fr) 2001-03-08
GB9903804D0 (en) 1999-04-14
JP2003514509A (ja) 2003-04-22
HK1040741A1 (zh) 2002-06-21

Similar Documents

Publication Publication Date Title
US20190225937A1 (en) Bank of stem cells for producing cells for transplantation having hla antigens matching those of transplant recipients and methods for making and using such a stem cell bank
US8273571B2 (en) Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues
Oback et al. Donor cells for nuclear cloning: many are called, but few are chosen
James et al. Contribution of human embryonic stem cells to mouse blastocysts
CA2387506C (fr) Production gynogenetique ou androgenetique de cellules et de lignees cellulaires pluripotentes et leur utilisation dans la production de cellules et de tissus differencies
US20040120932A1 (en) In vitro-derived adult pluripotent stem cells and uses therefor
Lewandowski et al. Techniques of human embryonic stem cell and induced pluripotent stem cell derivation
Flasza et al. Reprogramming in inter-species embryonal carcinoma–somatic cell hybrids induces expression of pluripotency and differentiation markers
KR101538089B1 (ko) 배아줄기세포-유사 세포
Do et al. Reprogramming somatic gene activity by fusion with pluripotent cells
Ma Biomaterials and regenerative medicine
Muzaffar et al. Equivalency of buffalo (Bubalus bubalis) embryonic stem cells derived from fertilized, parthenogenetic, and hand-made cloned embryos
EP1513928B1 (fr) Banque de cellules souches destinees a la production de cellules pour transplantation possedant des antigenes hla correspondant a ceux des receveurs de transplant, et procedes de constitution et d'utilisation d'une telle banque de cellules souches
CA2371900A1 (fr) Cellules-2 pluripotentes
AU2564100A (en) Pluripotential cells-1
Serov et al. Reprogramming mediated by cell fusion technology
Tada Nuclear reprogramming: an overview
Tada Nuclear Reprogramming
Du et al. Developmental incompatibility of human parthenogenetic embryonic stem cells in mouse blastocysts
Wenceslau et al. De-Differentiation of somatic cells to a pluripotent state
Goh Using mouse embryonic fibroblast (MEF) as feeder cells for production of embryonic stem cell (ESC) line in the murine and caprine/Goh Siew Ying
Ying Using Mouse Embryonic Fibroblast (MEF) as Feeder Cells for Production of Embryonic Stem Cell (ESC) Line in the Murine and Caprine
Qiang Human Pluripotent Stem Cells In In vitro Conditions: Differentiation And Genomic Instability

Legal Events

Date Code Title Description
FZDE Dead